This led to the recommendation that CF patients consume a high-fat diet containing Ͼ6% linoleic acid. We hypothesized that increased conversion of linoleic acid to arachidonic acid in CF leads to increased levels of arachidonate-derived proinflammatory metabolites and that this process is exacerbated by increasing linoleic acid levels in the diet. To test this hypothesis, we determined the effect of linoleic acid supplementation on downstream proinflammatory biomarkers in two CF models: 1) in vitro cell culture model using 16HBE14o
kines and neutrophils (16, 20) , and these increased levels even supersede the levels found in the BAL fluid from non-CF children with documented bacterial infection of the lower airways (17, 21) . Increased proinflammatory mediators are similarly present in the lungs of cftr Ϫ/Ϫ mice challenged with P. aeruginosa or LPS endotoxin (11) . These data indicate that CFTR mutations can lead to an excessive inflammatory response in the lung. This appears to be a constitutive abnormality, since CF bronchial submucosal glands cultured from CF patients show an increase in basal IL-6 and IL-8 levels compared with those cultured from non-CF patient (15, 29) .
One possible explanation for the altered innate immune response of CF patients is the CF-related defect in fatty acid metabolism, which is characterized by low linoleic acid and docosahexaenoic acid levels in plasma and in most tissues that is not explained by malnutrition but rather is mediated by CFTR dysfunction (9, 24) . Although levels of linoleic acid (18:2n-6) , an essential fatty acid, are low in CF, there is often a reciprocal increase in the downstream fatty acid arachidonic acid (20:4n-6) . This has been shown in vitro using CF human airway cells in culture (1, 5) , in vivo in CF knockout mice (10) , and in the plasma and tissues from humans with CF (9) . Recently, it was shown that the low linoleic acid levels in 16HBE14o Ϫ and IB3 human CF cells are most likely due to increased conversion to arachidonic acid via an increase in ⌬-6 desaturase, the rate-limiting enzyme in the pathway between linoleic and arachidonic acid (1, 5) . These findings are consistent with the observation of elevated arachidonic acid in the phospholipid fraction from BAL fluid in CF patients (13) . Given that arachidonic acid is the major fatty acid precursor of prostaglandins, which also are increased in CF patients (28) , the increased conversion and production of arachidonic acid may contribute to the altered inflammatory response observed in the CF airway. The increased conversion of linoleic acid to arachidonic acid in CF patients has important clinical implications. Because of the low linoleic acid levels that have been noted and previously regarded to be largely a result of a deficiency in this essential fatty acid, CF patients are now advised to consume diets high in linoleic acid.
Based on these data, we hypothesized that increasing the nutritional intake of linoleic acid, and thereby increasing linoleic acid levels, will lead to an increased production of arachidonic acid. In addition, we hypothesized that increased levels of arachidonic acid will result in an increased production of arachidonate-derived inflammatory mediators (25) noted both in cell culture and in the BAL of CF knockout mice in vivo.
MATERIALS AND METHODS

Cell culture. 16HBE14o
Ϫ cells, a human bronchial epithelial cell line originally established by Dr. Dieter Gruenert and a kind gift from Dr. Pamela Davis, were stably transfected with sense [wild-type (WT)] or antisense (CF) CFTR (18) . The CF phenotypic 16HBE cell line does not respond to cAMP agonists with increased chloride secretion, whereas the WT cells demonstrate a significant response (22) . The cells were cultured in 5% CO2 at 37°C in flasks coated with LHC basal media coating solution containing 0.01 mg/ml human fibronectin (Gibco, Grand Island, NY), 1% (vol/vol) Vitrogen-50 (Angiotech Biomaterials, Palo Alto, CA), and 0.1 mg/ml BSA. Cell culture medium consisted of MEM with GlutaMAX and supplemented with penicillin (100 U/ml), streptomycin (100 g/ml), and 10% horse serum.
Cell stimulation with bacteria and linoleic acid. The P. aeruginosa strain PAO1-V was kindly provided by Dr. Gerald Pier. PAO1-V was grown overnight at 37°C in trypticase soy broth. The bacteria were diluted to an optical density of 0.1 at 650 nm and grown in a liquid culture to an optical density of 0.4. Aliquots of the cultures were sedimented and washed three times by resuspending in PBS (Invitrogen, Carlsbad, CA). Finally, the bacteria were resuspended in serum and antibiotic-free MEM.
Confluent monolayers of sense and antisense cells were grown for 7 days in absence or presence of supplemental linoleic acid (Nu-Chek Prep, Elysian, MN). Given that sense cells were smaller than the antisense cells, sense cells were plated at threefold initial higher density than antisense cells to reach confluence at the same time for experimental use. In the experiments where bacteria were added, cells were then incubated for 60 min at 37°C with varying concentrations of PAO1-V. At the end of the incubation, the cells were washed three times with PBS, and the cells were then incubated for 20 h with MEM. The medium was removed and stored at Ϫ20°C for cytokine and eicosanoid analysis. In some experiments, the cells were also stimulated with various concentrations of PGE2 (Cayman Chemical, Ann Arbor, MI) or acetylsalicylic acid (Sigma, St. Louis, MO) with PAO1-V.
ELISA analysis. When cells were confluent, total protein was measured with no significant differences found between WT and CF cells. Monolayers of confluent cells were then stimulated, and cytokines or eicosanoids were analyzed in the supernatant.
IL-8 cytokine assay. The IL-8 concentration in the media was measured by a double-ligand ELISA as described previously (34) . Briefly, the wells of a 96-well plate (Fisher Scientific, Pittsburgh, PA) were coated with anti-human IL-8 at a concentration of 5 g/ml in PBS. After overnight incubation, the plate was washed with PBS with 0.05% Tween 20 (PBS-T; pH 7.4). Nonspecific binding was blocked with 1% BSA in PBS for Ն1 h at room temperature. The plates were washed, 50 l of the recombinant human IL-8 standard or samples was added to the wells, and the plates were incubated for 50 min at 37°C. Biotinylated anti-IL-8 was added after the plates were washed with PBS-T, and the plates were incubated for 50 min at 37°C. The plates were washed, streptavidin-horseradish peroxidase complex was added, and the plates were incubated for 20 min at room temperature in the dark. After the plates were carefully washed with PBS-T, 100 l of tetramethylbenzidine substrate solution (Kirkegaard and Perry Laboratories, Gaithersburg, MD) was added to each well, and the reaction was stopped with 50 l of 2 N sulfuric acid. The optical density at 450 nm was read with an automated microplate photometer (VERSAmax, Sunnyvale, CA), and the concentration of IL-8 was determined by using a standard curve.
Eicosanoid assay. PGE2 and PGF2␣ were measured in the supernatant using a commercially available kit from Neogen (Lexington, KY).
Western blot analysis. Sense and antisense CFTR cells were plated on 6-well plates, treated with either 0 or 60 M linoleic acid for 30 min or 24 h, and then exposed to 10 6 /ml PAO1-V for 15 min. Equal amounts of proteins were resolved on a 4 -12% Bis-Tris gel (Invitrogen), transferred onto Immobilon-P (Millipore, Billerica, MA), and then immunoblotted for phosphorylated or control ERK1/2, JNK, or p38 (Cell Signaling Technology, Beverly, MA) and NF-B (Delta Biolabs, Gilroy, CA).
Mouse colony. Experiments were carried out under protocols approved by the Beth Israel Deaconess Medical Center Animal Care Committee. UNC exon 10 cftr Ϫ/Ϫ (CF) mice and cftr ϩ/ϩ (WT) littermates were bred from heterozygous cftr ϩ/Ϫ mice from our established breeding colony at Beth Israel Deaconess Medical Center. The mice were housed in the animal facility in a room that was controlled for temperature (20 -22°C) , humidity (30 -70%), and light (light 6 AM to 8 PM). Tail-clip samples of 14-day-old mice were used for genotype analysis. The mice were weaned at an average of 23 days of age. The CF mice were maintained on Purina mouse chow and GoLYTELY (Braintree Laboratories) in the drinking water. Before the experiments, CF and WT littermates were put on Peptamen (Nestlé Nutrition, Minnetonka, MN) and water ad libitum for 4 days.
Linoleic acid feeding and LPS challenge. For studies determining the effect of in vivo pretreatment of linoleic acid, age-matched WT and cftr Ϫ/Ϫ littermate mice were used. Mice (ϳ50 days of age) were fed for 10 days with either 100 mg/day linoleic acid or oleic acid (Nu-Chek Prep) emulsified in Peptamen. Starting on day 8, a single dose of aerosolized Pseudomonas LPS (10 mg/15 g body wt) was administered over 15 min daily for 3 days. Pseudomonas LPS (Sigma) was sonicated in saline and administered at 20 lb./in.
2 with a nebulizer connected to a compressed air tank, which was connected to a large plastic container with vent holes into which the animals were placed. The mice were killed 3 h after the last LPS exposure. BAL was then performed with four aliquots of 1 ml of sterile saline. Saline was injected through polyethylene tubing placed into the upper airway after an incision into the trachea. Each aliquot of saline was introduced and removed slowly over 1 min to minimize trauma and hence red blood cell contamination. One-milliliter aliquots provided optimal lavage of the lungs without significant trauma. Neutrophils were obtained after centrifugation of BAL fluid at room temperature for 8 min at 800 g. The resulting pellet was resuspended in 50 l of PBS, and the neutrophil concentration was determined by counting the cells with a hemocytometer in a phase-contrast microscope. Neutrophils were positively identified by myeloperoxidase staining using tetramethylbenzidine-H 2O2 as the peroxidase substrate. In addition, it has been shown by histology that under these conditions an overwhelming predominance of neutrophils are present in the airways with Ͻ1% mononuclear cells (11) .
Lipid analysis. Lipids were extracted from cells or snap-frozen lung tissues from oleic or linoleic acid-supplemented CF and WT mice. Fatty acids were methylated and analyzed by gas chromatographymass spectrometry (GC/MS) as previously described (2, 5).
Statistical analysis. The in vitro experiments were repeated 5 times with the exception of the Western blot studies, where 3 separate experiments were performed. For the in vivo studies, a total of 12 mice were studied (6 WT and 6 CF). Statistical differences between groups were evaluated with Student's t-test. ANOVA was used when comparing Ͼ2 data points between groups. Data are presented as the mean Ϯ standard error of the mean.
RESULTS
Linoleic acid supplementation increases arachidonic acid levels selectively in CF cells. Previously, we (5) have shown that fatty acid metabolism in the n-6 pathway is dysregulated in CF; therefore, we hypothesized that in CF but not WT cells the addition of linoleic acid would lead to a selective increase in arachidonic acid. To test this hypothesis, 16HBE sense (WT) and antisense cells (CF) were grown to confluence and then incubated with 0 or 120 M linoleic acid for 7 days. The endogenous levels of all fatty acids, expressed as mean mole percent (mol%) Ϯ SE, in the two cell types are listed in Table 1 . Of specific interest, in absence of additional linoleic acid supplementation, linoleic acid levels in CF cells were 7.71 Ϯ 0.13 mol% compared with 9.17 Ϯ 0.08 mol% in WT cells (P Ͻ 0.001; Fig. 1A) ; levels of arachidonic acid were similar in both WT and CF cells (13.04 Ϯ 0.22 and 11.01 Ϯ 0.95 mol%; Fig. 1B) .
The levels of all fatty acids after supplementation in the media with 120 M linoleic acid for 7 days are given in Table 2 . Linoleic acid supplementation led to an ϳ3-fold increase in linoleic acid levels in both WT and CF cells (23.4 Ϯ 0.34 and 24.2 Ϯ 0.40 mol%, respectively), which were not statistically different from each other; however, these levels were significantly increased compared with unsupplemented levels of that cell type (P Ͻ 0.0001; Fig. 1A ). Examination of arachidonic acid levels in WT cells showed no statistically significant changes in response to linoleic acid supplementation. In contrast, arachidonic acid levels significantly increased in CF cells when supplemented with linoleic acid compared with no supplementation (11.01 Ϯ 0.95 vs. 17.31 Ϯ 0.16, respectively; P Ͻ 0.001). The arachidonic acid levels in supplemented CF cells also were increased compared with WT cells supplemented with linoleic acid (17.31 Ϯ 0.17 vs. 14.61 Ϯ 0.11, respectively; P Ͻ 0.001; Fig. 1B ). Notable changes in other fatty acids (Table 2) comparing WT with CF cells following linoleic supplementation included changes in precursors of arachidonic acid as well as a decrease in docosahexaenoic acid levels.
Linoleic acid supplementation increases IL-8 secretion in response to P. aeruginosa (PAO1-V).
Next, we examined whether the increase in arachidonic acid levels in CF cells resulted in an increased production of proinflammatory mediators that are involved in the pathogenesis of CF disease. IL-8, the proinflammatory chemokine for neutrophils, was measured in the cell culture medium 20 h after a 1-h exposure to three different concentrations of P. aeruginosa (PAO1-V) (Fig. 2) . Of note, there was minimal IL-8 secretion in the absence of PAO1-V for both sense and antisense cells cultured in 0, 60, and 120 M linoleic acid supplementation (0.005, 0.005, and 0.018 vs. 0.01, 0.018, and 0.025 ng/ml, respectively).
In the absence of linoleic acid supplementation, both WT and CF cells showed a dose-dependent trend in the increase in IL-8 secretion in response to increasing amounts of PAO1-V. IL-8 secretion was higher in CF cells compared with WT cells at all concentrations of bacteria examined. In WT cells, linoleic acid supplementation did not produce a statistically significant increase in IL-8 secretion compared with no supplementation at each of the concentrations of bacteria examined.
In contrast, CF cells demonstrated a significant increase in IL-8 secretion from cells supplemented with 60 M linoleic acid exposed to 10 4 /ml or 10 5 /ml PAO1-V (P Ͻ 0.05), with human bronchial epithelial cells. Fatty acids were analyzed by gas chromatography-mass spectrometry (GC/MS). Data represent mol% of linoleic acid and arachidonic acid relative to total fatty acid content as the means Ϯ SE. **P Ͻ 0.01, ***P Ͻ 0.001, ****P Ͻ 0.0001. similar increases observed in cells supplemented with 120 M linoleic acid exposed to 10 5 /ml and 10 6 /ml PAO1-V (P Ͻ 0.05).
Linoleic acid supplementation increases eicosanoid secretion in response to P. aeruginosa (PAO1-V). Eicosanoids are formed through the cyclooxygenase and 5-lipoxygenase pathways using arachidonic acid as substrate. We examined the effect of supplemental linoleic acid on the two downstream eicosanoids, PGE 2 and PGF 2␣ . At baseline, the synthesis of PGE 2 in response to 10 5 /ml PAO1-V was significantly higher in CF cells compared with WT cells (P Ͻ 0.01), which was further increased in CF cells, but not in WT cells, supplemented with 120 M linoleic acid ( Fig. 3A ; P Ͻ 0.01). Although at baseline there was no difference in PGF 2␣ synthesis between WT and CF cells, supplementation with 120 M linoleic acid led to a significant increase (P Ͻ 0.01) only in the CF cells (Fig. 3B) .
Since linoleic acid supplementation leads to a selective increase in eicosanoids in CF cells, we examined whether PGE 2 can regulate IL-8 secretion. PGE 2 has been shown to activate either the cyclooxygenase or lipoxygenase pathway to stimulate IL-8 secretion in other cell systems (33) . There was a positive dose-dependent trend in IL-8 secretion in both WT and CF cells incubated with increasing concentrations of PGE 2 ; CF cells showed a three-to fourfold increase in total IL-8 secretion compared with WT cells at all concentrations of PGE 2 examined (Fig. 4A) . At a PGE 2 concentration of 10 M, both WT and CF cells resulted in an increase in IL-8 production compared with cells in the absence of PGE 2 stimulation (P Ͻ 0.05), with the absolute production of IL-8 being greater in CF cells compared with WT cells. However, the fact that the magnitude of IL-8 secretion in response to PGE 2 was similar in WT and CF cells suggests that PGE 2 -stimulated IL-8 secretion is not directly modulated by the level of CFTR function.
To determine whether the PAO1-V induction of IL-8 secretion is dependent on the cyclooxygenase pathway, cells were incubated with acetylsalicylic acid for 3 h. As shown in Fig.  4B , inhibition of cyclooxygenase with 10 mM acetylsalicylic acid following PAO1-V exposure led to a significant decrease in IL-8 secretion in both the WT and CF cells. No inhibition was seen with zileuton, a 5-lipoxygenase inhibitor, a major converting enzyme, and a critical component of the pathway to downstream products from the lipoxygenase pathway. Although zileuton provides an incomplete inhibition of the lipoxygenase pathway, the lack of any inhibition indicates that PAO1-V is regulating IL-8 secretion predominantly through the cyclooxygenase pathway.
Linoleic acid supplementation does not alter MAPK signaling. Supplemental linoleic acid has been shown to activate MAPK signaling in endothelial cells (14, 33) . We tested whether the MAPKs ERK1/2, JNK, and p38 are selectively activated by linoleic acid supplementation in CF 16HBE14o Ϫ cells. Although the active (phosphorylated) form of ERK1 and -2 was increased in CF cells compared with WT cells, there was no further increase in the levels of ERK with supplemental linoleic acid in the presence of PAO1-V (10 6 /ml) in the medium (Fig. 5A ). JNK and p38 were not detectable (data not shown). Likewise, we also analyzed NF-B levels in WT and CF cells by Western blot analysis (Fig. 5B) Fig. 6A ). Arachidonic acid levels were increased only in the CF mice in response to increased linoleic acid in the diet ( Fig. 6B ; P Ͻ 0.05).
We (11) have previously shown that CF mice exposed to aerosolized Pseudomonas LPS led to increased neutrophils in BAL fluid compared with their WT littermates. As shown in Fig. 7 , CF mice fed 100 mg/day linoleic acid for 10 days demonstrated a fivefold increase in neutrophils in BAL fluid following LPS exposure compared with CF mice fed the control fatty acid diet (oleic acid; P Ͻ 0.0001).
DISCUSSION
Linoleic acid (18:2n-6) and ␣-linolenic acid (18:3n-3) are essential fatty acids and precursors to the production of longchain polyunsaturated fatty acids (PUFAs). The presence and balance of these essential fatty acids and the resultant downstream long-chain PUFAs are vital for multiple cellular functions, including membrane integrity and signaling, which together modulate the inflammatory response, regulate hormone production, and maintain physiological homeostatic processes ultimately conferring short-and long-term health benefits.
It has been well-described that CF is associated with low levels of linoleic acid in cells and in plasma (8, 9) . Furthermore, it has been proposed that linoleic acid deficiency may contribute to some of the health consequences seen in CF, especially in children. Within a cohort of CF and pancreatic insufficient patients between 7 and 10 yr of age, plasma levels of linoleic acid were inversely correlated with triene-to-tet- raene ratios; furthermore, linoleic acid levels Ͻ21 mol% were also associated with worse growth and pulmonary outcomes compared with CF children within this cohort who had plasma linoleic acid levels Ն21 mol% (19) . In addition, the importance of linoleic acid in infant growth may be dependent on the baseline nutritional status. In a longitudinal analysis of nutritional intake and growth in children with CF, increased energy intake alone was sufficient for catch-up growth (a return to birth weight z-score within 2 yr of diagnosis) for children diagnosed early by newborn screening, whereas increased energy and increased dietary intake of linoleic acid were both necessary to achieve catch-up growth for those diagnosed later in infancy (26) .
Potential explanations for low linoleic acid levels in CF have included fat malabsorption, decreased dietary fat intake, and altered fatty acid metabolism (8, 27) . To overcome the dietary deficiencies and insufficient utilization of linoleic acid secondary to fat malabsorption, an increase in total dietary intake of linoleic acid has been proposed as a strategy to achieve adequate circulating levels of linoleic acid and improve the clinical outcomes in CF. Increasing dietary intake of linoleic acid does appear to have some benefit on growth during infancy. Infants with CF who were fed a predigested formula with increased linoleic acid content (12 vs. 7% energy) demonstrated greater head growth and a trend for improved weight gain compared with infants with CF who were fed a formula with a lower amount of linoleic acid content (30) . Of note, however, is that the potential clinical benefits of increased dietary linoleic acid in CF has mostly been studied in the younger pediatric population, and the effect of increased linoleic acid intake in the older pediatric (adolescents) and adult populations has largely been unstudied.
A concern with increasing the dietary intake of linoleic acid is the potential secondary downstream effects of increased production of arachidonic acid and proinflammatory mediators. We (5) and others (6) have demonstrated that low circulating levels of linoleic acid may not be solely explained by insufficient dietary intake and fat malabsorption, but rather it may be partly due to an increase in utilization and conversion to downstream fatty acids in the n-6 fatty acid pathway. There appears to be no detrimental, proinflammatory effect of increasing dietary intake in a healthy population (12) ; however, this has not been specifically studied in CF. Thus the primary goal of this study was to determine whether increased dietary linoleic acid results in an increase in the production of arachidonic acid and downstream proinflammatory markers in CF cells and CF mice.
We found that additional intake and/or supplementation with linoleic acid was associated with increased arachidonic acid (20:4n-6) levels in CF cells and mice but not in WT cells or animals. Furthermore, the selective effect of linoleic acid supplementation in CF cells is linked to an increase in the secretion of the arachidonic acid metabolites, specifically the PGE 2 and PGF 2␣ . In addition, we found that elevated linoleic acid levels are associated with increased secretion of the neutrophil chemokine IL-8 selectively in CF but not in control 16HBE human airway cells and with increased neutrophil infiltration in the airways of CF mice. This process appears to be mediated predominantly via the cyclooxygenase pathway as inhibition of the cyclooxygenase but not lipoxygenase pathway blocked the linoleic acid-driven increase in IL-8 in response to PAO1-V.
There are several mechanisms by which supplemental linoleic acid increases the genesis of inflammatory mediators in CF cells. One possible mechanism is through increased MAPK signaling. These signaling pathways regulate the NF-Bdriven expression of vascular adhesion molecules in endothelial cells, leading to endothelial cell activation and an inflammatory response. However, although there was increased ERK signaling in CF cells compared with WT, there was no additional effect after incubation with linoleic acid and exposure to PAO1-V. Likewise, we did not find increased NF-B signaling in CF cells under these same conditions. These data are consistent with recent published data demonstrating that IL-8 production can be independent of NF-B activity in CF respiratory epithelial cells (7) . A second possible mechanism is through direct stimulation by P. aeruginosa. Certain strains of P. aeruginosa have been shown to secrete 15-lipoxygenase (31) . Although we demonstrated that zileuton did not inhibit IL-8 production, zileuton does not inhibit 15-lipoxygenase; thus it is possible that exposure to PAO1-V still was able to mediate downstream production of eicosanoids from arachidonic acid stimulating production of IL-8.
However, our data indicate that the increased production of arachidonic acid via linoleic acid supplementation predisposes the host to an increase in inflammatory mediators. This may be due to the host's endogenous ability to increase the production of eicosanoids from arachidonic acid or via the additive effect of an organism that has the innate ability to participate in the increased conversion of arachidonic acid substrate to downstream mediators. The finding that PGE 2 induced IL-8 secretion is increased in CF compared with WT cells independent of linoleic acid supplementation suggests that PGE 2 , which is known to be pro-and anti-inflammatory, is exerting proinflammatory effects. The relative increase in PGE 2 -stimulated IL-8 secretion being similar for both WT and CF cells suggests that this pathway is independent of CFTR function.
In the nondiseased, nonstressed state, increased linoleic acid intake does not appear to lead to an active proinflammatory response (12) . However, in conditions with baseline altered regulation of inflammation, our study lends additional support that increased intake or supplementation with linoleic acid may, in fact, lead to an increase in expression of proinflammatory mediators. For example, Alzoghaibi et al. (4) showed that linoleic acid-induced IL-8 secretion through arachidonic acid metabolites occurred in smooth muscle cells from Crohn's patients but was not observed in normal cells. However, in the presence of oxidative stress, normal cells also secreted IL-8 in response to linoleic acid (3). The authors concluded that linoleic acid had an impact on IL-8 secretion only when NF-B was activated, either spontaneously in Crohn's cells or through induction of oxidative stress in normal cells. This is relevant for the situation in CF cells where NF-B activity is constitutively increased through the loss of negative regulation by CFTR (32) . Thus our findings add to the general premise that in preexisting conditions of altered inflammatory regulation, the exposure to increased linoleic acid may potentiate an already dysregulated inflammatory response.
Reconciliation of the beneficial findings of increased linoleic acid and growth during infancy and the findings of increased production of arachidonic acid and proinflammatory markers with linoleic acid exposure seen in this study must be considered with caution. First, it is unknown how our findings translate to CF in humans. Second, it is possible that the inflammatory response to increasing linoleic acid may be developmentally regulated such that the response in infancy or childhood may be quite different compared with adolescence or adulthood. Finally, the risk-benefit of increasing dietary linoleic acid likely needs to be reevaluated during multiple time points. For example, the benefit of improved growth, especially head circumference, during infancy may outweigh the possible increase in arachidonic acid and downstream inflammatory markers. Infant weight gain and head growth is intricately related to neurodevelopmental outcomes and the benefit of adequate linoleic acid levels in this process cannot be ignored. However, during later childhood and into adulthood, growth attainment becomes less important, and the risk-benefit of additional linoleic acid exposure may shift such that the potential health detriment of propagating an active inflammatory process predominates.
In summary, we found that the loss of normal CFTR function results in a pathological inflammatory response to increased linoleic acid in vitro and in vivo with exposure to P. aeruginosa. These findings have important clinical significance for CF patients in light of the current recommendation to increase linoleic acid intake due to the deficiency of systemic linoleic acid levels found in this population. Increasing linoleic acid supplementation may incite and/or propagate inflammation and have detrimental clinical consequences. A clinical trial of linoleic acid supplementation in CF patients to examine the potential effect on inflammatory regulation is currently being undertaken.
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